Aspergillosis Treatment Market Size & Share, By Type (Allergic, Chronic, Invasive Aspergillosis); Drug Class (Corticosteroids, Anti-Fungal), Route of Administration (Oral Drugs, Ointments, Powder); Distribution Channels (Hospital Pharmacy, Retail Pharmacy) - Global Supply and Demand Analysis, Growth Forecast, Statistics Report 2024-2036

  • Report ID: 5410
  • Published Date: Nov 28, 2023
  • Report Format: PDF, PPT

Companies Dominating the Aspergillosis Treatment Market

top-features-companies
    • Bayer AG
      • Company Overview
      • Business Planning
      • Main Product Offerings
      • Financial Execution
      • Main Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • WOT Analysis
    • Mayne Pharma Group Limited
    • PULMATRiX Inc.
    •  Endo International plc
    • Johnson & Johnson Services Inc.
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Abbott
    • Takeda Pharmaceutical Company Limited

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Endo International plc released of the first generic Noxafil (posaconazole) Injection marks a substantial growth in the aspergillosis treatment market. This generic posaconazole injection is particularly created to identify invasive aspergillosis in patients aged 13 and above, surrounding both adults and pediatric populations.Candida infections in clients who are at significant risk of creating these infections because of being seriously immunocompromised, like hematopoietic stem cell transplant (HSCT) payees with graft-versus-host disease (GVHD) or those with hematologic enmities with extended neutropenia (low white blood cell counts) from chemotherapy.
  • Mayne Pharma Group Limited got approval from U.S.FDA for TolsuraTM (SUBA-Itraconazole Capsules). TOLSURA is a novel itraconazole development implemented to cure systemic fungal infections like aspergillosis, blastomycosis, and histoplasmosis. Tolsura is suggested for the therapy of blastomycosis (pulmonary and extrapulmonary), histoplasmosis (involving chronic cavitary pulmonary disease and disseminated non-meningeal histoplasmosis), and aspergillosis (pulmonary and extrapulmonary, in sufferers who are weak or who are stubborn to amphotericin B therapy).

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5410
  • Published Date: Nov 28, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing cases of aspergillosis in people will majorly drive the market growth of Aspergillosis Treatment market.

The market size of Aspergillosis Treatment market is expected to get a CAGR of ~4% over the forecast period, i.e., 2024-2036.

The major players in the market are Bayer AG, Mayne Pharma Group Limited, PULMATRiX Inc., Endo International Plc, Johnson & Johnson Services Inc., GlaxoSmithKline Plc, Pfizer Inc., Abbott, Takeda Pharmaceutical Company Limited, Novartis AG, Shionogi & Co., Ltd., Asahi Kasei Pharma Corporation, F2G Ltd., Regeneron Pharmaceutical Inc.

The allergic aspergillosis segment is anticipated to reap the largest market size by the end of 2036 and show substantial growth scopes.

The market in the North America region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying